Skip to main content

Table 3 Association between mammographic density and current use of menopausal hormone therapy stratified by genotypes of ten SNPs showing the lowest P values for interaction

From: A comprehensive evaluation of interaction between genetic variants and use of menopausal hormone therapy on mammographic density

SNP

SNP type

Chr

Gene

Density measure

Homozygous reference genotype (N)

Heterozygous genotype (N)

Homozygous non-reference genotype (N)

P interaction

Betaa (95 % CI)

P

Betaa (95 % CI)

P

Betaa (95 % CI)

P

 
     

T/T (2000)

 

T/G (3167)

 

G/G (1131)

  

rs9358531

Imputed

6

6.5 kb 5′ of PRL

PD

0.23 (0.08, 0.38)

2.5 × 10−03

0.46 (0.34, 0.58)

5.1 × 10−14

0.69 (0.49, 0.89)

1.4 × 10−11

0.0004

DA

0.38 (0.18, 0.58)

2.1 × 10−04

0.6 (0.44, 0.76)

1.2 × 10−13

0.85 (0.59, 1.12)

2.7 × 10−10

0.008

NDA

−0.17 (−0.39, 0.05)

1.4 × 10−01

−0.29 (−0.47, −0.12)

1.2 × 10−03

−0.58 (−0.87, −0.29)

1.0 × 10−04

0.02

     

G/G (2138)

 

G/A (3142)

 

A/A (1018)

  

rs9356811

Imputed

6

5.2 kb 5′ of PRL

PD

0.24 (0.1, 0.39)

1.1 × 10−03

0.48 (0.36, 0.6)

1.3 × 10−14

0.69 (0.48, 0.9)

1.5 × 10−10

0.0004

DA

0.39 (0.2, 0.59)

6.6 × 10−05

0.6 (0.44, 0.76)

1.9 × 10−13

0.89 (0.61, 1.17)

4.6 × 10−10

0.005

NDA

−0.17 (−0.38, 0.05)

1.2 × 10−01

−0.33 (−0.51, −0.15)

2.5 × 10−04

−0.51 (−0.82, −0.2)

1.1 × 10−03

0.05

     

C/C (2158)

 

C/T (3124)

 

T/T (1016)

  

rs10946546

Imputed

6

17 kb 5′ of PRL

PD

0.22 (0.07, 0.37)

3.2 × 10−03

0.51 (0.39, 0.63)

2.2 × 10−16

0.63 (0.42, 0.84)

3.0 × 10−09

0.0004

DA

0.39 (0.19, 0.58)

9.0 × 10−05

0.64 (0.48, 0.8)

4.8 × 10−15

0.77 (0.49, 1.05)

4.9 × 10−08

0.02

NDA

−0.11 (−0.32, 0.1)

3.1 × 10−01

−0.37 (−0.55, −0.2)

3.4 × 10−05

−0.49 (−0.8, −0.19)

1.5 × 10−03

0.01

     

T/T (2230)

 

T/C (3093)

 

C/C (975)

  

rs9393273

Imputed

6

8.1 kb 5′ of PRL

PD

0.24 (0.1, 0.39)

7.8 × 10−04

0.49 (0.37, 0.61)

4.8 × 10−15

0.68 (0.47, 0.89)

5.0 × 10−10

0.0005

DA

0.4 (0.21, 0.59)

3.6 × 10−05

0.62 (0.46, 0.78)

8.5 × 10−14

0.86 (0.58, 1.15)

2.4 × 10−09

0.01

NDA

−0.16 (−0.37, 0.05)

1.3 × 10−01

−0.33 (−0.51, −0.16)

2.4 × 10−04

−0.54 (−0.85, −0.23)

6.9 × 10−04

0.03

     

A/A (2079)

 

A/G (3154)

 

G/G (1065)

  

rs12525289

Imputed

6

9.9 kb 5′ of PRL

PD

0.24 (0.09, 0.39)

1.5 × 10−03

0.47 (0.35, 0.59)

2.0 × 10−14

0.68 (0.47, 0.88)

7.8 × 10−11

0.0005

DA

0.4 (0.2, 0.59)

7.3 × 10−05

0.59 (0.43, 0.76)

4.3 × 10−13

0.88 (0.61, 1.15)

2.1 × 10−10

0.009

NDA

−0.14 (−0.35, 0.08)

2.1 × 10−01

−0.34 (−0.51, −0.16)

1.9 × 10−04

−0.53 (−0.82, −0.23)

5.4 × 10−04

0.03

     

G/G (2090)

 

G/A (3142)

 

A/A (1066)

  

rs12199382

Imputed

6

24 kb 5′ of PRL

PD

0.21 (0.07, 0.36)

4.5 × 10−03

0.51 (0.39, 0.63)

1.8 × 10−16

0.62 (0.41, 0.82)

2.8 × 10−09

0.0006

DA

0.37 (0.17, 0.56)

2.5 × 10−04

0.65 (0.49, 0.81)

1.7 × 10−15

0.76 (0.49, 1.03)

3.5 × 10−08

0.02

NDA

−0.13 (−0.35, 0.08)

2.2 × 10−01

−0.35 (−0.53, −0.17)

1.1 × 10−04

−0.49 (−0.79, −0.2)

1.1 × 10−03

0.02

     

G/G (2629)

 

G/A (2873)

 

A/A (796)

  

rs9542456

Genotyped

13

505 kb 3′ of ATXN8OS

PD

0.59 (0.46, 0.73)

4.7 × 10−18

0.33 (0.2, 0.45)

4.1 × 10−07

0.22 (−0.01, 0.45)

5.9 × 10−02

0.0009

DA

0.75 (0.57, 0.93)

2.0 × 10−16

0.45 (0.28, 0.61)

1.8 × 10−07

0.44 (0.14, 0.75)

4.7 × 10−03

0.02

NDA

−0.43 (−0.63, −0.24)

1.6 × 10−05

−0.27 (−0.45, −0.08)

4.7 × 10−03

0.02 (−0.32, 0.36)

9.2 × 10−01

0.02

     

T/T (2241)

 

T/G (3092)

 

G/G (965)

  

rs12524161

Imputed

6

46 kb 5′ of PRL

PD

0.26 (0.12, 0.41)

2.8 × 10−04

0.47 (0.35, 0.6)

3.9 × 10−14

0.68 (0.47, 0.89)

4.6 × 10−10

0.001

DA

0.42 (0.23, 0.61)

1.2 × 10−05

0.6 (0.44, 0.76)

4.8 × 10−13

0.86 (0.58, 1.14)

2.6 × 10−09

0.01

NDA

−0.14 (−0.35, 0.06)

1.7 × 10−01

−0.34 (−0.51, −0.16)

2.3 × 10−04

−0.57 (−0.88, −0.26)

3.3 × 10−04

0.02

     

C/C (5358)

 

C/T (899)

 

T/T (41)

  

rs17861099

Imputed

15

462 bp 5′ of CYP1A1

PD

0.48 (0.39, 0.58)

2.4 × 10−21

0.09 (−0.14, 0.32)

4.3 × 10−01

−0.22 (−1.8, 1.37)

7.9 × 10−01

0.001

DA

0.65 (0.52, 0.78)

1.1 × 10−21

0.13 (−0.17, 0.43)

3.9 × 10−01

0.01 (−2.09, 2.1)

9.9 × 10−01

0.002

NDA

−0.35 (−0.5, −0.21)

1.8 × 10−06

0.02 (−0.32, 0.35)

9.2 × 10−01

−0.18 (−2.48, 2.13)

8.8 × 10−01

0.04

     

G/G (5337)

 

G/A (923)

 

A/A (38)

  

rs17861118

Imputed

15

8.3 kb 5′ of CYP1A1

PD

0.49 (0.39, 0.59)

2.6 × 10−21

0.1 (−0.12, 0.33)

3.8 × 10−01

−0.23 (−1.81, 1.35)

7.8 × 10−01

0.001

DA

0.66 (0.52, 0.79)

3.4 × 10−22

0.09 (−0.21, 0.39)

5.6 × 10−01

−0.02 (−2.11, 2.08)

9.9 × 10−01

0.0006

NDA

−0.34 (−0.49, −0.19)

5.0 × 10−06

−0.08 (−0.41, 0.24)

6.1 × 10−01

−0.18 (−2.48, 2.13)

8.8 × 10−01

0.08

  1. aAdjusted for study, reference age, case status, former use of menopausal hormone therapy, body mass index, number of pregnancies and principal components. SNP single nucleotide polymorphism, Chr chromosome, PD percent density (%), square-root-transformed, DA dense area (cm2), square-root-transformed, NDA non-dense area (cm2), square-root-transformed